| 000 | 01800 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250518004052.0 | ||
| 264 | 0 | _c20190930 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a1995-9133 | ||
| 024 | 7 |
_a10.1016/j.jmii.2018.10.002 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aChen, Cheng-Pin | |
| 245 | 0 | 0 |
_aEvaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings. _h[electronic resource] |
| 260 |
_bJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi _cAug 2019 |
||
| 300 |
_a556-562 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Observational Study | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAntiviral Agents _xeconomics |
| 650 | 0 | 4 |
_aCoinfection _xdrug therapy |
| 650 | 0 | 4 | _aCost-Benefit Analysis |
| 650 | 0 | 4 |
_aDrug Therapy, Combination _xeconomics |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHIV Infections _xcomplications |
| 650 | 0 | 4 | _aHealth Care Costs |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPrisons |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 |
_aRibavirin _xeconomics |
| 650 | 0 | 4 | _aTaiwan |
| 650 | 0 | 4 | _aViral Load |
| 700 | 1 | _aCheng, Chien-Yu | |
| 700 | 1 | _aZou, Huachun | |
| 700 | 1 | _aCheng, Chun-Han | |
| 700 | 1 | _aCheng, Shu-Hsing | |
| 700 | 1 | _aChen, Cheng-Kuo | |
| 700 | 1 | _aChen, Ching-Hsiang | |
| 700 | 1 | _aBair, Ming-Jong | |
| 773 | 0 |
_tJournal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi _gvol. 52 _gno. 4 _gp. 556-562 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.jmii.2018.10.002 _zAvailable from publisher's website |
| 999 |
_c28978220 _d28978220 |
||